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The problem
The Filoviridae family of negative-strand RNA viruses is feared for these viruses’ ability to 
cause hemorrhage and death in infected individuals. Depending on the infecting species of 
virus, the case fatality rate can be anywhere from 30 to 90% [1]. Ebola virus (EBOV), Sudan 
virus (SUDV) and Bundibugyo virus (BDBV) are the three clinically significant species that 
cause Ebola virus disease (EVD). These viruses are typically found in sub-Saharan Africa, 
and cause sporadic outbreaks that can be brought under control with appropriate rapid public 
health responses. However, the recent emergence of EBOV in west Africa in early 2014 [2] 
has been challenging to contain, and has spread to three countries in the region so far. This 
outbreak, now the largest EBOV outbreak on record, is still ongoing at the time of writing 
this editorial.
Efforts by many investigators have led to the development of potential vaccines and 
therapeutics [3,4]. However, none of these have yet resulted in commercially available 
products, and are unlikely to do so in the near future due to the cost of developing novel 
products for human use and the challenges of conducting a clinical trial during an outbreak 
in a developing nation that lacks the necessary healthcare infrastructure. The most cost-
effective and timely option would be to identify an already approved drug that might be 
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effective at combating disease caused by EBOV and SUDV for off-label use by treating 
physicians. In order to identify currently licensed drugs that might be beneficial, we need to 
know more about the pathophysiology of the disease. Biomarker analyses could prove to be 
useful for this purpose.
What we know
EBOV selectively targets antigen-presenting cells & hepatocytes
Two main cellular tropisms have been defined for EBOV and SUDV. The viruses readily 
infect cells of the monocyte/macrophage lineage, including dendritic cells and hepatocytes. 
Other infected cell types, including endothelial cells, have been noted in animal models and 
autopsy specimens but are typically found late in infection when viral loads are high. 
Consistent with the theory that infection of antigen-presenting cells and hepatocytes is 
responsible for the majority of EBOV’s pathogenesis is the finding that mice, which are 
naturally resistant to EBOV, can develop severe, lethal and human-like diseases if they are 
engrafted with human CD34+ hematopoietic stem cells and autologous human liver and 
thymus [Bird B, Unpublished data].
Biomarkers can indicate the severity of the disease as well as its putative mechanisms
One way in which investigators have attempted to study EVD in humans is by measuring 
various analytes in serum or plasma specimens obtained from infected individuals. This type 
of analysis has been done in humans for EBOV, SUDV and BDBV.
Ebola virus
While EBOV research is ever expanding, the currently available biomarker data are limited. 
Two separate investigations used ELISAs or multiplex assays of serum and plasma samples, 
as well as RT-PCR from PBMC RNA, to analyze biomarkers in EBOV-infected individuals 
from six different outbreaks. They reported increased levels of IL-1β, IL1-RA, IL-2, IL-6, 
IL-8, IL-10, MIP-1α, MIP-1β, MCP-1, MCSF, MIF, IP-10, GRO-α, eotaxin, neopterin, 
sTNF-RI, TNF-α, sFasL, sFas, IFN-α and IFN-γ [5–8]. These data gave rise to the concept 
that excessive immune activation, or ‘cytokine storm’, upon EBOV infection is detrimental 
to infected individuals. Unfortunately, these findings are relatively nonspecific, because 
there is no way to determine the contribution of each cytokine to the pathophysiology of 
EVD, and, as discussed below, contradictory data exist on the role of cytokines in EVD.
In addition to the increased sFasL and sFas levels seen in the above-mentioned studies, 
direct analyses of infected PMBCs found DNA laddering and lymphopenia as well as 
increased CD95 (Fas) staining by flow cytometric evaluation. Together, these findings 
demonstrate that lymphocyte apoptosis is induced by EBOV infection. Moreover, 
lymphocyte apoptosis was associated with fatal outcomes [7,8].
Studies of individuals with asymptomatic EBOV infections complicate the ‘cytokine storm’ 
concept, however. These studies demonstrate pro-inflammatory cytokine level magnitudes 
higher than those seen in symptomatic individuals, but only in asymptomatic samples 
collected the week following virus exposure [9]. Serial sampling of these asymptomatic 
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individuals shows rapid declines in pro-inflammatory cytokine levels even before EBOV is 
fully cleared or an antibody response develops. Therefore, these cytokine responses in 
themselves are not detrimental to the host. Rather, the timing of the response and/ or its 
subsequent downregulation seems to be important for survival. In a further study of PMBC 
RNA from the same asymptomatic patients, the investigators identified biomarkers of T-cell 
activation: IL-2, IL-4, CD-28, CD-40L and CTLA-4 were all upregulated immediately after 
the initial pro-inflammatory cytokine burst [10]. Additionally, using RNA biomarkers of 
apoptosis and T-cell activity, including perforin, Fas, FasL and IFN-γ, they found evidence 
of contraction of the T-cell population occurring at the same time as antibody development 
in these patients, consistent with an appropriate adaptive response.
Bundibugyo virus
Even fewer biomarker studies have been conducted with BDBV. One small study found that 
samples from fatal cases had increased levels of IFN-α2, IFN-γ and IL-10 [11]; these 
findings were consistent with what has been reported for EBOV.
Sudan virus
Prior to the current EBOV outbreak in West Africa, the Gulu outbreak of SUDV in 2000–
2001 was the largest outbreak of EVD ever recorded [12]. An international team responded, 
and serial specimens were saved from many of the affected patients, making hundreds of 
samples available for testing. Much of what we know about EVD has come from analyses of 
these specimens. Levels of aspartate aminotransferase and D-dimer were elevated in patients 
who had a fatal outcome [13]. These biomarker elevations are consistent with liver tropism, 
and indicate possible contribution of coagulopathy to EVD. Nitric oxide, a reactive oxygen 
species that could be associated with the hypotension/shock that is seen in EVD, was also 
elevated in fatal cases [14].
The large number of available specimens from the Gulu outbreak permitted the analysis of 
cytokines and chemokines over time in serial specimens obtained from 150 patients. The 
analyses showed that IL-6, IL-8, IL-10 and MIP-1β were higher in patients with fatal 
outcomes, but IFN-α was higher in patients who survived [15]. The idea that the ‘cytokine 
storm’ is detrimental, therefore, is quite an over simplification, since IFN-α, a notable pro-
inflammatory antiviral cytokine, was associated with survival, while IL-10, a cytokine with 
known anti-inflammatory properties, was associated with a fatal outcome. Rather, an overall 
immune dysregulation appears to exist at the cytokine level, followed by reduced numbers 
of total and activated CD8 T cells in SUDV-infected patients who have a fatal outcome [14].
The massive growth in the number of commercially available multiplex assays for 
biomarker analysis permitted us to go back to these same serum specimens and conduct 
novel biomarker assays, since these can be performed with small amounts of patient 
specimens. In our recent study, we reported that sCD40L was associated with survival [16], 
a finding that suggests the possible role of activated platelets in promoting survival, and/or 
the possibility that sCD40L can stimulate antigen-presenting cells to overcome SUDV-
induced inhibition of these cells [17]. This finding in particular has significant implications 
for EVD management in patients, and suggests two potential therapies: platelet 
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administration (already indicated, since many patients are thrombocytopenic), or 
recombinant CD-40L administration. The latter strategy has already been used in patients 
with hyper-IgM, a disorder in which CD-40L is missing or defective [18].
Additionally, we found that thrombomodulin levels were elevated in patients with a fatal 
outcome, as well as in patients who had hemorrhagic manifestations [16]. Thrombomodulin 
functions in endothelial stability when it is present on the endothelium rather than free-
floating in the serum, and also in inhibiting the coagulation pathway. Our finding 
underscores the complex interaction between the endothelium, the immune system and the 
coagulation pathway. In fact, therapies that provide increased stability to the endothelium 
will likely benefit patients not only by improving hemodynamic stability, but also by 
decreasing the likelihood of hemorrhagic manifestations.
What we need to know & how to get there
Absolutely critical to improving our ability to combat EVD is a thorough understanding of 
the mechanisms of this disease. A significant amount of aberrant immune signaling is 
detected in fatal cases, and this is accompanied by the lack of an effective adaptive response. 
Therefore, analyses of the cellular immune response in samples from both symptomatic and 
asymptomatic cases will be essential. Clearly, some aspects of the immune response are 
beneficial to the host, so defining exactly which aspects these are, and the kinetics of when 
they need to occur, will be very helpful for our understanding of EVD pathogenesis. 
Acquiring this knowledge will require serial sampling of patients during outbreaks, proper 
handling and storage of specimens and qualified personnel and facilities to carry out the 
studies. Coordination between clinicians and researchers will be necessary to ensure that this 
is done in an ethically sound manner. Biomarker analyses of patient specimens has given us 
an immense amount of information about EVD, but in order to go full circle, we need to use 
this information to guide future studies with the ultimate goal of improving patient care, 
mitigating disease and saving lives.
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